Friday, September 23, 2022


Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment

Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion of a $132 million Series B financing led by...

Ionis Provides Update on Development Program Evaluating PCSK9 Antisense Medicine

Ionis Pharmaceuticals, Inc. announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 (AZD8233) administered...

FDA Grants QT Imaging Clearance to Calculate Fibroglandular Volume of the Breast

The U.S. Food and Drug Administration (FDA) has granted QT Imaging, Inc. 510(K) clearance to calculate the fibroglandular volume (FGV) of the breast and...

Brooks Rehabilitation Participates in National Stroke Recovery Trial Using Breakthrough Technology

Brooks Rehabilitation first participant in the national stroke recovery trial, EMAGINE, has just completed study participation. The randomized, double-blind study tests whether a non-invasive,...

Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0803 for the Treatment of Amyotrophic Lateral Sclerosis

Cellenkos, Inc., a clinical stage biotech company that focuses on developing transformative cellular therapeutics for treatment of inflammatory disorders and autoimmune diseases, today announced...

Hot Topics